nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—CYSLTR2—female reproductive system—skin cancer	0.018	0.0793	CbGeAlD
Nedocromil—HSP90AA1—endothelium—skin cancer	0.0176	0.0777	CbGeAlD
Nedocromil—HSP90AA1—hair follicle—skin cancer	0.0173	0.0764	CbGeAlD
Nedocromil—FPR1—lymphoid tissue—skin cancer	0.0168	0.074	CbGeAlD
Nedocromil—HSP90AA1—blood vessel—skin cancer	0.0163	0.0716	CbGeAlD
Nedocromil—FPR1—head—skin cancer	0.0135	0.0596	CbGeAlD
Nedocromil—PTGDR—head—skin cancer	0.0128	0.0563	CbGeAlD
Nedocromil—HSP90AA1—nipple—skin cancer	0.0118	0.0518	CbGeAlD
Nedocromil—HSP90AA1—neck—skin cancer	0.0116	0.0512	CbGeAlD
Nedocromil—Disorder sight—Imiquimod—skin cancer	0.0112	0.0338	CcSEcCtD
Nedocromil—PTGDR—lymph node—skin cancer	0.00895	0.0394	CbGeAlD
Nedocromil—HSP90AA1—connective tissue—skin cancer	0.00834	0.0367	CbGeAlD
Nedocromil—HSP90AA1—epithelium—skin cancer	0.00792	0.0349	CbGeAlD
Nedocromil—CYSLTR1—mammalian vulva—skin cancer	0.00791	0.0349	CbGeAlD
Nedocromil—HSP90AA1—skin of body—skin cancer	0.00753	0.0332	CbGeAlD
Nedocromil—CYSLTR1—lymphoid tissue—skin cancer	0.00703	0.0309	CbGeAlD
Nedocromil—Rash erythematous—Imiquimod—skin cancer	0.00693	0.021	CcSEcCtD
Nedocromil—HSP90AA1—mammalian vulva—skin cancer	0.00687	0.0302	CbGeAlD
Nedocromil—Otitis media—Imiquimod—skin cancer	0.00682	0.0206	CcSEcCtD
Nedocromil—CYSLTR1—female reproductive system—skin cancer	0.00678	0.0298	CbGeAlD
Nedocromil—Feeling hot—Imiquimod—skin cancer	0.00677	0.0205	CcSEcCtD
Nedocromil—Disorder sight—Temozolomide—skin cancer	0.00668	0.0202	CcSEcCtD
Nedocromil—Stinging—Imiquimod—skin cancer	0.00655	0.0198	CcSEcCtD
Nedocromil—HSP90AA1—lymphoid tissue—skin cancer	0.0061	0.0269	CbGeAlD
Nedocromil—HSP90AA1—female reproductive system—skin cancer	0.00588	0.0259	CbGeAlD
Nedocromil—Viral infection—Imiquimod—skin cancer	0.00588	0.0178	CcSEcCtD
Nedocromil—CYSLTR1—head—skin cancer	0.00566	0.0249	CbGeAlD
Nedocromil—HSP90AA1—head—skin cancer	0.00491	0.0216	CbGeAlD
Nedocromil—Arthritis—Vemurafenib—skin cancer	0.00465	0.0141	CcSEcCtD
Nedocromil—Dysgeusia—Vismodegib—skin cancer	0.00431	0.0131	CcSEcCtD
Nedocromil—Eczema—Imiquimod—skin cancer	0.00429	0.013	CcSEcCtD
Nedocromil—Nasal congestion—Imiquimod—skin cancer	0.00423	0.0128	CcSEcCtD
Nedocromil—Otitis media—Temozolomide—skin cancer	0.00409	0.0124	CcSEcCtD
Nedocromil—Arthritis—Imiquimod—skin cancer	0.00397	0.012	CcSEcCtD
Nedocromil—CYSLTR1—lymph node—skin cancer	0.00396	0.0175	CbGeAlD
Nedocromil—Eosinophilia—Vemurafenib—skin cancer	0.00387	0.0117	CcSEcCtD
Nedocromil—Stinging—Fluorouracil—skin cancer	0.00362	0.011	CcSEcCtD
Nedocromil—Viral infection—Temozolomide—skin cancer	0.00352	0.0107	CcSEcCtD
Nedocromil—HSP90AA1—lymph node—skin cancer	0.00344	0.0152	CbGeAlD
Nedocromil—Influenza—Imiquimod—skin cancer	0.00333	0.0101	CcSEcCtD
Nedocromil—Bronchitis—Imiquimod—skin cancer	0.0032	0.0097	CcSEcCtD
Nedocromil—Dyspepsia—Vismodegib—skin cancer	0.00317	0.00958	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Vismodegib—skin cancer	0.0031	0.0094	CcSEcCtD
Nedocromil—Fatigue—Vismodegib—skin cancer	0.0031	0.00938	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Imiquimod—skin cancer	0.0031	0.00937	CcSEcCtD
Nedocromil—Pain—Vismodegib—skin cancer	0.00307	0.00931	CcSEcCtD
Nedocromil—Gastrointestinal pain—Vismodegib—skin cancer	0.00294	0.0089	CcSEcCtD
Nedocromil—Conjunctivitis—Imiquimod—skin cancer	0.00289	0.00874	CcSEcCtD
Nedocromil—Abdominal pain—Vismodegib—skin cancer	0.00284	0.0086	CcSEcCtD
Nedocromil—Arthritis—Bleomycin—skin cancer	0.00282	0.00853	CcSEcCtD
Nedocromil—Sinusitis—Imiquimod—skin cancer	0.00279	0.00844	CcSEcCtD
Nedocromil—Rash erythematous—Docetaxel—skin cancer	0.00276	0.00837	CcSEcCtD
Nedocromil—Photophobia—Fluorouracil—skin cancer	0.00275	0.00833	CcSEcCtD
Nedocromil—Otitis media—Docetaxel—skin cancer	0.00272	0.00823	CcSEcCtD
Nedocromil—Ear pain—Temozolomide—skin cancer	0.00271	0.0082	CcSEcCtD
Nedocromil—Rhinitis—Imiquimod—skin cancer	0.00267	0.00809	CcSEcCtD
Nedocromil—Dysgeusia—Vemurafenib—skin cancer	0.00267	0.00807	CcSEcCtD
Nedocromil—Pharyngitis—Imiquimod—skin cancer	0.00265	0.00801	CcSEcCtD
Nedocromil—Gastroenteritis—Temozolomide—skin cancer	0.00261	0.00789	CcSEcCtD
Nedocromil—Asthenia—Vismodegib—skin cancer	0.00258	0.00781	CcSEcCtD
Nedocromil—Visual impairment—Imiquimod—skin cancer	0.00257	0.00778	CcSEcCtD
Nedocromil—Nasal congestion—Temozolomide—skin cancer	0.00254	0.00768	CcSEcCtD
Nedocromil—Diarrhoea—Vismodegib—skin cancer	0.00246	0.00745	CcSEcCtD
Nedocromil—Cough—Vemurafenib—skin cancer	0.00238	0.00719	CcSEcCtD
Nedocromil—Vomiting—Vismodegib—skin cancer	0.00229	0.00692	CcSEcCtD
Nedocromil—Rash—Vismodegib—skin cancer	0.00227	0.00686	CcSEcCtD
Nedocromil—Dermatitis—Vismodegib—skin cancer	0.00227	0.00686	CcSEcCtD
Nedocromil—Anaphylactic shock—Vemurafenib—skin cancer	0.00222	0.00672	CcSEcCtD
Nedocromil—Nausea—Vismodegib—skin cancer	0.00214	0.00647	CcSEcCtD
Nedocromil—Pneumonia—Bleomycin—skin cancer	0.00212	0.00643	CcSEcCtD
Nedocromil—Cough—Imiquimod—skin cancer	0.00203	0.00613	CcSEcCtD
Nedocromil—Pneumonia—Dactinomycin—skin cancer	0.00198	0.00599	CcSEcCtD
Nedocromil—Chest pain—Imiquimod—skin cancer	0.00198	0.00598	CcSEcCtD
Nedocromil—Dry mouth—Imiquimod—skin cancer	0.00193	0.00585	CcSEcCtD
Nedocromil—Bronchitis—Temozolomide—skin cancer	0.00192	0.00581	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00192	0.00581	CcSEcCtD
Nedocromil—Fatigue—Vemurafenib—skin cancer	0.00192	0.0058	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Temozolomide—skin cancer	0.00186	0.00562	CcSEcCtD
Nedocromil—Eosinophilia—Fluorouracil—skin cancer	0.00182	0.00551	CcSEcCtD
Nedocromil—Pneumonia—Temozolomide—skin cancer	0.00179	0.00542	CcSEcCtD
Nedocromil—Body temperature increased—Vemurafenib—skin cancer	0.00176	0.00532	CcSEcCtD
Nedocromil—Pharyngitis—Dactinomycin—skin cancer	0.00175	0.00531	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00171	0.00518	CcSEcCtD
Nedocromil—Dyspnoea—Imiquimod—skin cancer	0.00169	0.00511	CcSEcCtD
Nedocromil—Sinusitis—Temozolomide—skin cancer	0.00167	0.00506	CcSEcCtD
Nedocromil—Dyspepsia—Imiquimod—skin cancer	0.00167	0.00505	CcSEcCtD
Nedocromil—Pneumonia—Fluorouracil—skin cancer	0.00165	0.00499	CcSEcCtD
Nedocromil—Hypersensitivity—Vemurafenib—skin cancer	0.00164	0.00495	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Imiquimod—skin cancer	0.00164	0.00495	CcSEcCtD
Nedocromil—Fatigue—Imiquimod—skin cancer	0.00163	0.00494	CcSEcCtD
Nedocromil—Pain—Imiquimod—skin cancer	0.00162	0.0049	CcSEcCtD
Nedocromil—HSP90AA1—Axon guidance—SCN10A—skin cancer	0.00161	0.00364	CbGpPWpGaD
Nedocromil—Conjunctivitis—Fluorouracil—skin cancer	0.00159	0.00483	CcSEcCtD
Nedocromil—Asthenia—Vemurafenib—skin cancer	0.00159	0.00482	CcSEcCtD
Nedocromil—Pharyngitis—Temozolomide—skin cancer	0.00159	0.0048	CcSEcCtD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—TERT—skin cancer	0.00157	0.00355	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Imiquimod—skin cancer	0.00155	0.00469	CcSEcCtD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.00155	0.0035	CbGpPWpGaD
Nedocromil—Visual impairment—Temozolomide—skin cancer	0.00154	0.00466	CcSEcCtD
Nedocromil—Sinusitis—Fluorouracil—skin cancer	0.00154	0.00466	CcSEcCtD
Nedocromil—FPR1—GPCR downstream signaling—MC1R—skin cancer	0.00154	0.00347	CbGpPWpGaD
Nedocromil—Diarrhoea—Vemurafenib—skin cancer	0.00152	0.0046	CcSEcCtD
Nedocromil—Urticaria—Imiquimod—skin cancer	0.00151	0.00456	CcSEcCtD
Nedocromil—Abdominal pain—Imiquimod—skin cancer	0.0015	0.00453	CcSEcCtD
Nedocromil—Body temperature increased—Imiquimod—skin cancer	0.0015	0.00453	CcSEcCtD
Nedocromil—PTGDR—GPCR downstream signaling—MC1R—skin cancer	0.00148	0.00335	CbGpPWpGaD
Nedocromil—Leukopenia—Bleomycin—skin cancer	0.00148	0.00447	CcSEcCtD
Nedocromil—Rhinitis—Fluorouracil—skin cancer	0.00148	0.00447	CcSEcCtD
Nedocromil—Dizziness—Vemurafenib—skin cancer	0.00147	0.00445	CcSEcCtD
Nedocromil—CYSLTR2—GPCR ligand binding—SHH—skin cancer	0.00147	0.00331	CbGpPWpGaD
Nedocromil—Pharyngitis—Fluorouracil—skin cancer	0.00146	0.00442	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—PTCH2—skin cancer	0.00146	0.0033	CbGpPWpGaD
Nedocromil—Cough—Bleomycin—skin cancer	0.00144	0.00436	CcSEcCtD
Nedocromil—CYSLTR1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00144	0.00325	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR ligand binding—MC1R—skin cancer	0.00143	0.00322	CbGpPWpGaD
Nedocromil—Vomiting—Vemurafenib—skin cancer	0.00141	0.00428	CcSEcCtD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—CDK4—skin cancer	0.00141	0.00317	CbGpPWpGaD
Nedocromil—Chest pain—Bleomycin—skin cancer	0.0014	0.00425	CcSEcCtD
Nedocromil—HSP90AA1—Signaling events mediated by VEGFR1 and VEGFR2—BRAF—skin cancer	0.0014	0.00317	CbGpPWpGaD
Nedocromil—Rash—Vemurafenib—skin cancer	0.0014	0.00424	CcSEcCtD
Nedocromil—Dermatitis—Vemurafenib—skin cancer	0.0014	0.00424	CcSEcCtD
Nedocromil—Hypersensitivity—Imiquimod—skin cancer	0.0014	0.00423	CcSEcCtD
Nedocromil—FPR1—Signaling by GPCR—MC1R—skin cancer	0.00139	0.00315	CbGpPWpGaD
Nedocromil—Headache—Vemurafenib—skin cancer	0.00139	0.00421	CcSEcCtD
Nedocromil—CYSLTR2—GPCR ligand binding—SMO—skin cancer	0.00139	0.00314	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR ligand binding—PTCH1—skin cancer	0.00139	0.00314	CbGpPWpGaD
Nedocromil—CYSLTR2—Endothelins—HRAS—skin cancer	0.00138	0.00311	CbGpPWpGaD
Nedocromil—Leukopenia—Dactinomycin—skin cancer	0.00138	0.00417	CcSEcCtD
Nedocromil—Dysgeusia—Temozolomide—skin cancer	0.00136	0.00412	CcSEcCtD
Nedocromil—Asthenia—Imiquimod—skin cancer	0.00136	0.00411	CcSEcCtD
Nedocromil—CYSLTR2—GPCR ligand binding—PTGER4—skin cancer	0.00135	0.00306	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—MC1R—skin cancer	0.00135	0.00304	CbGpPWpGaD
Nedocromil—Anaphylactic shock—Bleomycin—skin cancer	0.00135	0.00407	CcSEcCtD
Nedocromil—Nausea—Vemurafenib—skin cancer	0.00132	0.00399	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by ERBB2—FOXO4—skin cancer	0.00132	0.00297	CbGpPWpGaD
Nedocromil—Tremor—Temozolomide—skin cancer	0.0013	0.00395	CcSEcCtD
Nedocromil—Diarrhoea—Imiquimod—skin cancer	0.0013	0.00392	CcSEcCtD
Nedocromil—Dizziness—Imiquimod—skin cancer	0.00125	0.00379	CcSEcCtD
Nedocromil—Leukopenia—Temozolomide—skin cancer	0.00125	0.00377	CcSEcCtD
Nedocromil—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00123	0.00278	CbGpPWpGaD
Nedocromil—HSP90AA1—Class I PI3K signaling events—NRAS—skin cancer	0.00123	0.00277	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—RHOU—skin cancer	0.00123	0.00277	CbGpPWpGaD
Nedocromil—Cough—Temozolomide—skin cancer	0.00121	0.00367	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—FOXO4—skin cancer	0.00121	0.00274	CbGpPWpGaD
Nedocromil—Vomiting—Imiquimod—skin cancer	0.0012	0.00365	CcSEcCtD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.0012	0.00272	CbGpPWpGaD
Nedocromil—Dyspnoea—Bleomycin—skin cancer	0.0012	0.00363	CcSEcCtD
Nedocromil—Rash—Imiquimod—skin cancer	0.00119	0.00362	CcSEcCtD
Nedocromil—Dermatitis—Imiquimod—skin cancer	0.00119	0.00361	CcSEcCtD
Nedocromil—Pneumonia—Docetaxel—skin cancer	0.00119	0.0036	CcSEcCtD
Nedocromil—Headache—Imiquimod—skin cancer	0.00119	0.00359	CcSEcCtD
Nedocromil—CYSLTR2—GPCR downstream signaling—MC1R—skin cancer	0.00116	0.00263	CbGpPWpGaD
Nedocromil—Dry mouth—Temozolomide—skin cancer	0.00116	0.00351	CcSEcCtD
Nedocromil—HSP90AA1—Developmental Biology—SCN10A—skin cancer	0.00115	0.0026	CbGpPWpGaD
Nedocromil—Pain—Bleomycin—skin cancer	0.00115	0.00348	CcSEcCtD
Nedocromil—Conjunctivitis—Docetaxel—skin cancer	0.00115	0.00348	CcSEcCtD
Nedocromil—Leukopenia—Fluorouracil—skin cancer	0.00115	0.00347	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—PTCH2—skin cancer	0.00114	0.00257	CbGpPWpGaD
Nedocromil—Anaphylactic shock—Temozolomide—skin cancer	0.00114	0.00344	CcSEcCtD
Nedocromil—Nausea—Imiquimod—skin cancer	0.00113	0.00341	CcSEcCtD
Nedocromil—HSP90AA1—Corticotropin-releasing hormone—BRAF—skin cancer	0.0011	0.00249	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PTCH2—skin cancer	0.0011	0.00249	CbGpPWpGaD
Nedocromil—Chest pain—Fluorouracil—skin cancer	0.00109	0.0033	CcSEcCtD
Nedocromil—Fatigue—Dactinomycin—skin cancer	0.00108	0.00328	CcSEcCtD
Nedocromil—Pain—Dactinomycin—skin cancer	0.00107	0.00325	CcSEcCtD
Nedocromil—Urticaria—Bleomycin—skin cancer	0.00107	0.00324	CcSEcCtD
Nedocromil—Rhinitis—Docetaxel—skin cancer	0.00107	0.00323	CcSEcCtD
Nedocromil—Body temperature increased—Bleomycin—skin cancer	0.00106	0.00322	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—MC1R—skin cancer	0.00106	0.00239	CbGpPWpGaD
Nedocromil—HSP90AA1—Class I PI3K signaling events—KRAS—skin cancer	0.00105	0.00238	CbGpPWpGaD
Nedocromil—Pharyngitis—Docetaxel—skin cancer	0.00105	0.00319	CcSEcCtD
Nedocromil—Anaphylactic shock—Fluorouracil—skin cancer	0.00105	0.00317	CcSEcCtD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.00104	0.00234	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Dactinomycin—skin cancer	0.00103	0.00311	CcSEcCtD
Nedocromil—Visual impairment—Docetaxel—skin cancer	0.00102	0.0031	CcSEcCtD
Nedocromil—CYSLTR1—GPCR ligand binding—SHH—skin cancer	0.00102	0.0023	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PTCH2—skin cancer	0.00101	0.00229	CbGpPWpGaD
Nedocromil—Dyspnoea—Temozolomide—skin cancer	0.00101	0.00306	CcSEcCtD
Nedocromil—FPR1—GPCR downstream signaling—PTGER4—skin cancer	0.00101	0.00228	CbGpPWpGaD
Nedocromil—Dyspepsia—Temozolomide—skin cancer	0.000999	0.00303	CcSEcCtD
Nedocromil—FPR1—Signaling by GPCR—SHH—skin cancer	0.000993	0.00224	CbGpPWpGaD
Nedocromil—Abdominal pain—Dactinomycin—skin cancer	0.000992	0.003	CcSEcCtD
Nedocromil—Body temperature increased—Dactinomycin—skin cancer	0.000992	0.003	CcSEcCtD
Nedocromil—Hypersensitivity—Bleomycin—skin cancer	0.000992	0.003	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Temozolomide—skin cancer	0.00098	0.00297	CcSEcCtD
Nedocromil—Fatigue—Temozolomide—skin cancer	0.000979	0.00296	CcSEcCtD
Nedocromil—PTGDR—GPCR downstream signaling—PTGER4—skin cancer	0.000975	0.0022	CbGpPWpGaD
Nedocromil—HSP90AA1—LKB1 signaling events—TP53—skin cancer	0.000972	0.0022	CbGpPWpGaD
Nedocromil—Pain—Temozolomide—skin cancer	0.000971	0.00294	CcSEcCtD
Nedocromil—Asthenia—Bleomycin—skin cancer	0.000966	0.00292	CcSEcCtD
Nedocromil—CYSLTR1—GPCR ligand binding—PTCH1—skin cancer	0.000964	0.00218	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR ligand binding—SMO—skin cancer	0.000964	0.00218	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—SHH—skin cancer	0.000959	0.00217	CbGpPWpGaD
Nedocromil—CYSLTR1—Endothelins—HRAS—skin cancer	0.000954	0.00216	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—PTCH1—skin cancer	0.000942	0.00213	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—SMO—skin cancer	0.000942	0.00213	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR ligand binding—PTGER4—skin cancer	0.000938	0.00212	CbGpPWpGaD
Nedocromil—Dyspnoea—Fluorouracil—skin cancer	0.000933	0.00282	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—TLR7—skin cancer	0.00093	0.0021	CbGpPWpGaD
Nedocromil—Gastrointestinal pain—Temozolomide—skin cancer	0.000928	0.00281	CcSEcCtD
Nedocromil—HSP90AA1—Axon guidance—RASA1—skin cancer	0.000926	0.00209	CbGpPWpGaD
Nedocromil—Hypersensitivity—Dactinomycin—skin cancer	0.000925	0.0028	CcSEcCtD
Nedocromil—Dyspepsia—Fluorouracil—skin cancer	0.000921	0.00279	CcSEcCtD
Nedocromil—FPR1—Signaling by GPCR—PTGER4—skin cancer	0.000917	0.00207	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—PTCH1—skin cancer	0.000909	0.00205	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—SMO—skin cancer	0.000909	0.00205	CbGpPWpGaD
Nedocromil—Dysgeusia—Docetaxel—skin cancer	0.000906	0.00274	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000903	0.00273	CcSEcCtD
Nedocromil—Urticaria—Temozolomide—skin cancer	0.000902	0.00273	CcSEcCtD
Nedocromil—Asthenia—Dactinomycin—skin cancer	0.000901	0.00273	CcSEcCtD
Nedocromil—Body temperature increased—Temozolomide—skin cancer	0.000897	0.00272	CcSEcCtD
Nedocromil—Abdominal pain—Temozolomide—skin cancer	0.000897	0.00272	CcSEcCtD
Nedocromil—HSP90AA1—Class I PI3K signaling events—HRAS—skin cancer	0.000897	0.00203	CbGpPWpGaD
Nedocromil—Pain—Fluorouracil—skin cancer	0.000895	0.00271	CcSEcCtD
Nedocromil—PTGDR—Signaling by GPCR—PTGER4—skin cancer	0.000885	0.002	CbGpPWpGaD
Nedocromil—HSP90AA1—Aryl Hydrocarbon Receptor—HRAS—skin cancer	0.000881	0.00199	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RHOU—skin cancer	0.000879	0.00199	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—GLI2—skin cancer	0.000863	0.00195	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTCH2—skin cancer	0.000863	0.00195	CbGpPWpGaD
Nedocromil—Diarrhoea—Dactinomycin—skin cancer	0.000859	0.0026	CcSEcCtD
Nedocromil—Vomiting—Bleomycin—skin cancer	0.000856	0.00259	CcSEcCtD
Nedocromil—Rash—Bleomycin—skin cancer	0.000849	0.00257	CcSEcCtD
Nedocromil—Dermatitis—Bleomycin—skin cancer	0.000848	0.00257	CcSEcCtD
Nedocromil—Hypersensitivity—Temozolomide—skin cancer	0.000836	0.00253	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—GLI2—skin cancer	0.000834	0.00188	CbGpPWpGaD
Nedocromil—Urticaria—Fluorouracil—skin cancer	0.000831	0.00252	CcSEcCtD
Nedocromil—Leukopenia—Docetaxel—skin cancer	0.000828	0.00251	CcSEcCtD
Nedocromil—Body temperature increased—Fluorouracil—skin cancer	0.000827	0.0025	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—MC1R—skin cancer	0.000823	0.00186	CbGpPWpGaD
Nedocromil—Asthenia—Temozolomide—skin cancer	0.000815	0.00247	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—GLI1—skin cancer	0.000812	0.00183	CbGpPWpGaD
Nedocromil—Cough—Docetaxel—skin cancer	0.000807	0.00244	CcSEcCtD
Nedocromil—CYSLTR1—GPCR downstream signaling—MC1R—skin cancer	0.000806	0.00182	CbGpPWpGaD
Nedocromil—Nausea—Bleomycin—skin cancer	0.000799	0.00242	CcSEcCtD
Nedocromil—Vomiting—Dactinomycin—skin cancer	0.000798	0.00242	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—MC1R—skin cancer	0.000795	0.0018	CbGpPWpGaD
Nedocromil—Rash—Dactinomycin—skin cancer	0.000791	0.0024	CcSEcCtD
Nedocromil—Chest pain—Docetaxel—skin cancer	0.000788	0.00238	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—GLI1—skin cancer	0.000784	0.00177	CbGpPWpGaD
Nedocromil—Diarrhoea—Temozolomide—skin cancer	0.000777	0.00235	CcSEcCtD
Nedocromil—Hypersensitivity—Fluorouracil—skin cancer	0.000771	0.00233	CcSEcCtD
Nedocromil—Dry mouth—Docetaxel—skin cancer	0.00077	0.00233	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—SUFU—skin cancer	0.000769	0.00174	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—PTGER4—skin cancer	0.000765	0.00173	CbGpPWpGaD
Nedocromil—Anaphylactic shock—Docetaxel—skin cancer	0.000755	0.00229	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—SHH—skin cancer	0.000753	0.0017	CbGpPWpGaD
Nedocromil—Dizziness—Temozolomide—skin cancer	0.000751	0.00227	CcSEcCtD
Nedocromil—Nausea—Dactinomycin—skin cancer	0.000746	0.00226	CcSEcCtD
Nedocromil—PTGDR—Signaling Pathways—SUFU—skin cancer	0.000743	0.00168	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—MC1R—skin cancer	0.000732	0.00165	CbGpPWpGaD
Nedocromil—Vomiting—Temozolomide—skin cancer	0.000722	0.00219	CcSEcCtD
Nedocromil—Rash—Temozolomide—skin cancer	0.000716	0.00217	CcSEcCtD
Nedocromil—Diarrhoea—Fluorouracil—skin cancer	0.000716	0.00217	CcSEcCtD
Nedocromil—Dermatitis—Temozolomide—skin cancer	0.000715	0.00217	CcSEcCtD
Nedocromil—CYSLTR2—Signaling by GPCR—SMO—skin cancer	0.000714	0.00161	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—PTCH1—skin cancer	0.000714	0.00161	CbGpPWpGaD
Nedocromil—Headache—Temozolomide—skin cancer	0.000711	0.00215	CcSEcCtD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000705	0.00159	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—PTGER4—skin cancer	0.000695	0.00157	CbGpPWpGaD
Nedocromil—Dizziness—Fluorouracil—skin cancer	0.000692	0.00209	CcSEcCtD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—NRAS—skin cancer	0.000692	0.00156	CbGpPWpGaD
Nedocromil—Nausea—Temozolomide—skin cancer	0.000674	0.00204	CcSEcCtD
Nedocromil—Dyspnoea—Docetaxel—skin cancer	0.000673	0.00204	CcSEcCtD
Nedocromil—Vomiting—Fluorouracil—skin cancer	0.000665	0.00201	CcSEcCtD
Nedocromil—Dyspepsia—Docetaxel—skin cancer	0.000665	0.00201	CcSEcCtD
Nedocromil—HSP90AA1—Developmental Biology—RASA1—skin cancer	0.000661	0.00149	CbGpPWpGaD
Nedocromil—Rash—Fluorouracil—skin cancer	0.00066	0.002	CcSEcCtD
Nedocromil—Dermatitis—Fluorouracil—skin cancer	0.000659	0.00199	CcSEcCtD
Nedocromil—Headache—Fluorouracil—skin cancer	0.000655	0.00198	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—GLI2—skin cancer	0.000654	0.00148	CbGpPWpGaD
Nedocromil—Gastrointestinal disorder—Docetaxel—skin cancer	0.000652	0.00197	CcSEcCtD
Nedocromil—Fatigue—Docetaxel—skin cancer	0.000651	0.00197	CcSEcCtD
Nedocromil—Pain—Docetaxel—skin cancer	0.000646	0.00195	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—MC1R—skin cancer	0.000624	0.00141	CbGpPWpGaD
Nedocromil—Nausea—Fluorouracil—skin cancer	0.000621	0.00188	CcSEcCtD
Nedocromil—Gastrointestinal pain—Docetaxel—skin cancer	0.000617	0.00187	CcSEcCtD
Nedocromil—CYSLTR2—Signaling Pathways—GLI1—skin cancer	0.000615	0.00139	CbGpPWpGaD
Nedocromil—HSP90AA1—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	0.000613	0.00138	CbGpPWpGaD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000607	0.00137	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTCH2—skin cancer	0.000598	0.00135	CbGpPWpGaD
Nedocromil—HSP90AA1—Validated targets of C-MYC transcriptional activation—TP53—skin cancer	0.000598	0.00135	CbGpPWpGaD
Nedocromil—Body temperature increased—Docetaxel—skin cancer	0.000597	0.00181	CcSEcCtD
Nedocromil—Abdominal pain—Docetaxel—skin cancer	0.000597	0.00181	CcSEcCtD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—KRAS—skin cancer	0.000595	0.00134	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—MLH1—skin cancer	0.00059	0.00133	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—SHH—skin cancer	0.000587	0.00133	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SUFU—skin cancer	0.000583	0.00132	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—RASA1—skin cancer	0.000583	0.00132	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—TP53—skin cancer	0.00058	0.00131	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by VEGF—NRAS—skin cancer	0.000579	0.00131	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SHH—skin cancer	0.000567	0.00128	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—RASA1—skin cancer	0.000563	0.00127	CbGpPWpGaD
Nedocromil—Hypersensitivity—Docetaxel—skin cancer	0.000556	0.00168	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—PTCH1—skin cancer	0.000556	0.00126	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—SMO—skin cancer	0.000556	0.00126	CbGpPWpGaD
Nedocromil—Asthenia—Docetaxel—skin cancer	0.000542	0.00164	CcSEcCtD
Nedocromil—FPR1—Signaling Pathways—PTGER4—skin cancer	0.000541	0.00122	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—TLR7—skin cancer	0.000541	0.00122	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PTCH1—skin cancer	0.000537	0.00121	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—SMO—skin cancer	0.000537	0.00121	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—CDK4—skin cancer	0.000535	0.00121	CbGpPWpGaD
Nedocromil—HSP90AA1—Glucocorticoid receptor regulatory network—IL6—skin cancer	0.000531	0.0012	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PTGER4—skin cancer	0.00053	0.0012	CbGpPWpGaD
Nedocromil—HSP90AA1—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	0.000528	0.00119	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PTGER4—skin cancer	0.000523	0.00118	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—SHH—skin cancer	0.000522	0.00118	CbGpPWpGaD
Nedocromil—Diarrhoea—Docetaxel—skin cancer	0.000517	0.00156	CcSEcCtD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000516	0.00117	CbGpPWpGaD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—HRAS—skin cancer	0.000506	0.00114	CbGpPWpGaD
Nedocromil—Dizziness—Docetaxel—skin cancer	0.000499	0.00151	CcSEcCtD
Nedocromil—HSP90AA1—Signaling by VEGF—KRAS—skin cancer	0.000498	0.00113	CbGpPWpGaD
Nedocromil—HSP90AA1—EPH-Ephrin signaling—HRAS—skin cancer	0.000497	0.00112	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PTCH1—skin cancer	0.000495	0.00112	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—SMO—skin cancer	0.000495	0.00112	CbGpPWpGaD
Nedocromil—CYSLTR2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000494	0.00112	CbGpPWpGaD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	0.000489	0.0011	CbGpPWpGaD
Nedocromil—HSP90AA1—TNF alpha Signaling Pathway—IL6—skin cancer	0.000484	0.00109	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PLIN2—skin cancer	0.000483	0.00109	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PTGER4—skin cancer	0.000482	0.00109	CbGpPWpGaD
Nedocromil—Vomiting—Docetaxel—skin cancer	0.00048	0.00145	CcSEcCtD
Nedocromil—HSP90AA1—Innate Immune System—FOXO4—skin cancer	0.000479	0.00108	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—FOXO4—skin cancer	0.000478	0.00108	CbGpPWpGaD
Nedocromil—Rash—Docetaxel—skin cancer	0.000476	0.00144	CcSEcCtD
Nedocromil—Dermatitis—Docetaxel—skin cancer	0.000476	0.00144	CcSEcCtD
Nedocromil—Headache—Docetaxel—skin cancer	0.000473	0.00143	CcSEcCtD
Nedocromil—HSP90AA1—Disease—CSPG4—skin cancer	0.000465	0.00105	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—FOXO4—skin cancer	0.000462	0.00104	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—GLI2—skin cancer	0.000453	0.00102	CbGpPWpGaD
Nedocromil—Nausea—Docetaxel—skin cancer	0.000448	0.00136	CcSEcCtD
Nedocromil—HSP90AA1—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	0.000448	0.00101	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SHH—skin cancer	0.000445	0.001	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—RASA1—skin cancer	0.000442	0.000998	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—NRAS—skin cancer	0.000438	0.000989	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MC1R—skin cancer	0.000433	0.000977	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTCH2—skin cancer	0.000429	0.00097	CbGpPWpGaD
Nedocromil—HSP90AA1—VEGFA-VEGFR2 Pathway—IL6—skin cancer	0.000429	0.00097	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—GLI1—skin cancer	0.000426	0.000963	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by VEGF—HRAS—skin cancer	0.000423	0.000956	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SMO—skin cancer	0.000422	0.000952	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTCH1—skin cancer	0.000422	0.000952	CbGpPWpGaD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	0.000421	0.00095	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTGER4—skin cancer	0.00041	0.000927	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—CDKN2A—skin cancer	0.000409	0.000924	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by VEGF—IL6—skin cancer	0.000405	0.000915	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SUFU—skin cancer	0.000404	0.000913	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—NRAS—skin cancer	0.000403	0.000909	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CSPG4—skin cancer	0.000389	0.000879	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—KRAS—skin cancer	0.000377	0.000851	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—FOXO4—skin cancer	0.000362	0.000819	CbGpPWpGaD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	0.000357	0.000808	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—KRAS—skin cancer	0.000346	0.000783	CbGpPWpGaD
Nedocromil—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	0.000342	0.000773	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CDK4—skin cancer	0.000336	0.000758	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TERT—skin cancer	0.000335	0.000758	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GLI2—skin cancer	0.000325	0.000735	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—CDK4—skin cancer	0.000324	0.000732	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—HRAS—skin cancer	0.00032	0.000723	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TERT—skin cancer	0.000319	0.000722	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ENO2—skin cancer	0.000316	0.000714	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SHH—skin cancer	0.000316	0.000714	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MC1R—skin cancer	0.00031	0.000701	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TERT—skin cancer	0.000309	0.000697	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SHH—skin cancer	0.000308	0.000696	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by ERBB2—IL6—skin cancer	0.000306	0.000692	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—RASA1—skin cancer	0.000306	0.000692	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—GLI1—skin cancer	0.000306	0.000691	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CDK4—skin cancer	0.0003	0.000678	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—HRAS—skin cancer	0.000294	0.000665	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SMO—skin cancer	0.000292	0.00066	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTCH1—skin cancer	0.000292	0.00066	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SUFU—skin cancer	0.00029	0.000655	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTGER4—skin cancer	0.000284	0.000643	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling by EGFR in Cancer—IL6—skin cancer	0.000282	0.000637	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—FOXO4—skin cancer	0.000279	0.00063	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—NRAS—skin cancer	0.000269	0.000608	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ENO2—skin cancer	0.000265	0.000598	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—NRAS—skin cancer	0.00026	0.000587	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—FOXO4—skin cancer	0.000258	0.000582	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle, Mitotic—CDKN2A—skin cancer	0.000257	0.00058	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—BRAF—skin cancer	0.000253	0.000572	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—NRAS—skin cancer	0.000253	0.000571	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FOXO4—skin cancer	0.000251	0.000568	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—BRAF—skin cancer	0.000244	0.000552	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TERT—skin cancer	0.000242	0.000547	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—KRAS—skin cancer	0.000232	0.000523	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—CDKN2A—skin cancer	0.000229	0.000518	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—TP53—skin cancer	0.000228	0.000514	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—KRAS—skin cancer	0.000224	0.000505	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SHH—skin cancer	0.000221	0.0005	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RASA1—skin cancer	0.00022	0.000497	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—KRAS—skin cancer	0.000217	0.000491	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTCH1—skin cancer	0.00021	0.000474	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SMO—skin cancer	0.00021	0.000474	CbGpPWpGaD
Nedocromil—HSP90AA1—Cellular responses to stress—IL6—skin cancer	0.000208	0.000471	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTGER4—skin cancer	0.000204	0.000461	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—NRAS—skin cancer	0.000204	0.000461	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—HRAS—skin cancer	0.000197	0.000445	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—BRAF—skin cancer	0.000192	0.000433	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—HRAS—skin cancer	0.00019	0.00043	CbGpPWpGaD
Nedocromil—FPR1—Signaling by GPCR—IL6—skin cancer	0.000188	0.000426	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—HRAS—skin cancer	0.000185	0.000418	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERCC2—skin cancer	0.000184	0.000415	CbGpPWpGaD
Nedocromil—PTGDR—Signaling by GPCR—IL6—skin cancer	0.000182	0.000411	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FOXO4—skin cancer	0.00018	0.000407	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—NRAS—skin cancer	0.00018	0.000407	CbGpPWpGaD
Nedocromil—HSP90AA1—Axon guidance—IL6—skin cancer	0.000177	0.0004	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—KRAS—skin cancer	0.000176	0.000397	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TERT—skin cancer	0.000172	0.000389	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TERT—skin cancer	0.000168	0.000379	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—NRAS—skin cancer	0.000159	0.00036	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—NRAS—skin cancer	0.000159	0.000359	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—KRAS—skin cancer	0.000155	0.000351	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ERCC2—skin cancer	0.000154	0.000347	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—NRAS—skin cancer	0.000154	0.000347	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—skin cancer	0.000149	0.000337	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—skin cancer	0.000143	0.000323	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—NRAS—skin cancer	0.000141	0.000319	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—skin cancer	0.000137	0.00031	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—skin cancer	0.000137	0.000309	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—BRAF—skin cancer	0.000136	0.000308	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—BRAF—skin cancer	0.000133	0.0003	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—skin cancer	0.000132	0.000299	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—skin cancer	0.000132	0.000298	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—skin cancer	0.000128	0.000288	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—skin cancer	0.000126	0.000285	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—skin cancer	0.000122	0.000275	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—skin cancer	0.000122	0.000275	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—NRAS—skin cancer	0.000121	0.000272	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—skin cancer	0.00012	0.000272	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—skin cancer	0.000117	0.000265	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—skin cancer	0.000116	0.000263	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—skin cancer	0.000116	0.000263	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—skin cancer	0.000112	0.000254	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—skin cancer	0.000111	0.000252	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—skin cancer	0.000111	0.000252	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTGS2—skin cancer	0.00011	0.000249	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—skin cancer	0.000108	0.000243	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—skin cancer	0.000104	0.000234	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—skin cancer	0.000103	0.000234	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—skin cancer	9.9e-05	0.000224	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—BRAF—skin cancer	9.54e-05	0.000216	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—NRAS—skin cancer	9.27e-05	0.000209	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—skin cancer	9.22e-05	0.000208	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—skin cancer	9.22e-05	0.000208	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—skin cancer	8.82e-05	0.000199	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NRAS—skin cancer	8.56e-05	0.000193	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—skin cancer	8.44e-05	0.000191	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NRAS—skin cancer	8.35e-05	0.000189	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—skin cancer	7.98e-05	0.00018	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—skin cancer	7.37e-05	0.000166	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—skin cancer	7.19e-05	0.000162	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—skin cancer	6.78e-05	0.000153	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—skin cancer	6.49e-05	0.000147	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—skin cancer	6.39e-05	0.000144	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—skin cancer	6.26e-05	0.000142	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—skin cancer	6.11e-05	0.000138	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NRAS—skin cancer	6e-05	0.000135	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—skin cancer	5.99e-05	0.000135	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—skin cancer	5.85e-05	0.000132	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—skin cancer	5.16e-05	0.000117	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—skin cancer	4.59e-05	0.000104	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—skin cancer	4.39e-05	9.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—skin cancer	4.2e-05	9.48e-05	CbGpPWpGaD
